UCL Cancer Institute


Selected publications

  1. Liau, L. M., Ashkan, K., Brem, S., Campian, J. L., Trusheim, J. E., Iwamoto, F. M., Tran, D. D., Ansstas, G., Cobbs, C. S., Heth, J. A., Salacz, M. E., D'Andre, S., Aiken, R. D., Moshel, Y. A., Nam, J. Y., Pillainayagam, C. P., Wagner, S. A., Walter, K. A., Chaudhary, R., Goldlust, S. A., … Bosch, M. L. (2023). Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort TrialJAMA oncology9(1), 112–121. https://doi.org/10.1001/jamaoncol.2022.5370

  2. Brown, N. F., Ottaviani, D., Tazare, J., Gregson, J., Kitchen, N., Brandner, S., Fersht, N., & Mulholland, P. (2022). Survival Outcomes and Prognostic Factors in GlioblastomaCancers14(13), 3161. https://doi.org/10.3390/cancers14133161

  3. Tesileanu, C. M. S., Vallentgoed, W. R., Sanson, M., Taal, W., Clement, P. M., Wick, W., Brandes, A. A., Baurain, J. F., Chinot, O. L., Wheeler, H., Gill, S., Griffin, M., Rogers, L., Ruda, R., Weller, M., McBain, C., Reijneveld, J., Enting, R. H., Caparrotti, F., Lesimple, T., Clenton, S., Gijtenbeek, A., Lim, E., de Vos, F., Mulholland, P. J., Taphoorn, M. J. B., de Heer, I., Hoogstrate, Y., de Wit, M., Boggiani, L., Venneker, S., Oosting, J., Bovee, J., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Mason, W. P., Kros, J. M., Wesseling, P., Aldape, K., Jenkins, R. B., Dubbink, H. J., Baumert, B., Golfinopoulos, V., Gorlia, T., van den Bent, M. and French, P. J. (2021). Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathol 141(6): 945-957.

  4. Draaisma, K., Tesileanu, C. M. S., de Heer, I., Klein, M., Smits, M., Reijneveld, J. C., Clement, P. M., De Vos, F., Wick, A., Mulholland, P., Taphoorn, M., Weller, M., Chinot, O. L., Kros, J. M., Verschuere, T., Coens, C., Golfinopoulos, V., Gorlia, T., Idbaih, A., Robe, P. A., van den Bent, M. J. and French, P. J. (2022). Prognostic significance of DNA methylation profiles at MRI enhancing tumor recurrence: a report from the EORTC 26091 TAVAREC trial. Clin Cancer Res.
  5. Carter, T. J., Agliardi, G., Lin, F. Y., Ellis, M., Jones, C., Robson, M., Richard-Londt, A., Southern, P., Lythgoe, M., Zaw Thin, M., Ryzhov, V., de Rosales, R. T. M., Gruettner, C., Abdollah, M. R. A., Pedley, R. B., Pankhurst, Q. A., Kalber, T. L., Brandner, S., Quezada, S., Mulholland, P., Shevtsov, M. and Chester, K. (2021). Potential of Magnetic Hyperthermia to Stimulate Localized Immune Activation. Small 17(14): e2005241.

  6. Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., Phuphanich, S., Sepulveda, J. M., de Souza, P., Sahebjam, S., Carleton, M., Tatsuoka, K., Taitt, C., Zwirtes, R., Sampson, J., & Weller, M. (2020). Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. JAMA Oncology. 

  7. Brown, N. F., Ng, S. M., Brooks, C., Coutts, T., Holmes, J., Roberts, C., Elhussein, L., Hoskin, P., Maughan, T., Blagden, S., & Mulholland, P. (2020). A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: The Ipi-Glio trial protocol. BMC Cancer, 20(1). 
  8. Brown, N. F., Carter, T. J., Ottaviani, D., & Mulholland, P. (2018). Harnessing the immune system in glioblastoma. British Journal of Cancer, 119(10).
  9. Brown, N. F., Williams, M., Arkenau, H.-T., Fleming, R. A., Tolson, J., Yan, L., Zhang, J., Swartz, L., Singh, R., Auger, K. R., Lenox, L., Cox, D., Lewis, Y., Plisson, C., Searle, G., Saleem, A., Blagden, S., & Mulholland, P. (2018). A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [ 11 C]GSK2256098. Neuro-Oncology, 20(12).
  10. van den Bent, M. J., Klein, M., Smits, M., Reijneveld, J. C., French, P. J., Clement, P., de Vos, F. Y. F., Wick, A., Mulholland, P. J., Taphoorn, M. J. B., Lewis, J., Weller, M., Chinot, O. L., Kros, J. M., de Heer, I., Verschuere, T., Coens, C., Golfinopoulos, V., Gorlia, T., & Idbaih, A. (2018). Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. The Lancet Oncology, 19(9).
  11. Liau, L. M., Ashkan, K., Tran, D. D., Campian, J. L., Trusheim, J. E., Cobbs, C. S., Heth, J. A., Salacz, M., Taylor, S., D’Andre, S. D., Iwamoto, F. M., Dropcho, E. J., Moshel, Y. A., Walter, K. A., Pillainayagam, C. P., Aiken, R., Chaudhary, R., Goldlust, S. A., Bota, D. A., … Mulholland, P., Bosch, M. L. (2018). First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine, 16(1). 
  12. Brown, N. F., Carter, T., Kitchen, N., & Mulholland, P. (2017). Dabrafenib and trametinib in BRAFV600E mutated glioma. CNS Oncology, 6(4). 
  13. Bardella, C., Al-Dalahmah, O., Krell, D., Brazauskas, P., Al-Qahtani, K., Tomkova, M., Adam, J., Serres, S., Lockstone, H., Freeman-Mills, L., Pfeffer, I., Sibson, N., Goldin, R., Schuster-Böeckler, B., Pollard, P. J., Soga, T., McCullagh, J. S., Schofield, C. J., Mulholland, P., … Tomlinson, I. (2016). Expression of Idh1R132H in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis. Cancer Cell, 30(4).
  14. Brown, N., Carter, T., & Mulholland, P. (2017). Adjuvant Chemotherapy is Indicated in Patients with Lower Grade Glioma. Clinical Oncology, 29(3).
  15. Brown, N., McBain, C., Nash, S., Hopkins, K., Sanghera, P., Saran, F., Phillips, M., Dungey, F., Clifton-Hadley, L., Wanek, K., Krell, D., Jeffries, S., Khan, I., Smith, P., & Mulholland, P. (2016). Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma. PLoS ONE.
  16. Rampling, R., Peoples, S., Mulholland, P. J., James, A., Al-Salihi, O., Twelves, C. J., McBain, C., Jefferies, S., Jackson, A., Stewart, W., Lindner, J., Kutscher, S., Hilf, N., McGuigan, L., Peters, J., Hill, K., Schoor, O., Singh-Jasuja, H., Halford, S. E., & Ritchie, J. W. A. (2016). A cancer research UK first time in human phase i trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clinical Cancer Research, 22(19).
  17. Tudzarova, S., Mulholland, P., Dey, A., Stoeber, K., Okorokov, A. L., & Williams, G. H. (2016). p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress. Cell Cycle, 15(21).
  18. Carter, T., Shaw, H., Cohn-Brown, D., Chester, K., & Mulholland, P. (2015). Ipilimumab and Bevacizumab in Glioblastoma. Clinical Oncology.